Marie Thibault
Stock Analyst at BTIG
(3.47)
# 1,141
Out of 5,182 analysts
125
Total ratings
44.63%
Success rate
5.91%
Average return
Main Sectors:
Stocks Rated by Marie Thibault
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABT Abbott Laboratories | Reiterates: Buy | $131 | $93.69 | +39.82% | 18 | Apr 27, 2026 | |
| EW Edwards Lifesciences | Maintains: Buy | $98 → $100 | $81.76 | +22.31% | 4 | Apr 24, 2026 | |
| BSX Boston Scientific | Maintains: Buy | $90 → $80 | $59.00 | +35.59% | 17 | Apr 22, 2026 | |
| KMTS Kestra Medical Technologies | Reiterates: Buy | $32 | $22.75 | +40.66% | 4 | Apr 7, 2026 | |
| MMED MiniMed Group | Initiates: Buy | $25 | $12.91 | +93.72% | 1 | Mar 31, 2026 | |
| DXCM DexCom | Reiterates: Buy | $85 | $60.60 | +40.26% | 11 | Mar 9, 2026 | |
| DCTH Delcath Systems | Maintains: Buy | $23 → $19 | $10.72 | +77.24% | 5 | Feb 26, 2026 | |
| PODD Insulet | Reiterates: Buy | $380 | $186.46 | +103.80% | 7 | Feb 18, 2026 | |
| MASI Masimo | Downgrades: Neutral | n/a | $178.50 | - | 8 | Feb 18, 2026 | |
| ATRC AtriCure | Reiterates: Buy | $54 | $29.22 | +84.80% | 8 | Feb 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $17 → $15 | $4.35 | +244.83% | 3 | Feb 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $25 | $9.24 | +170.56% | 4 | Feb 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $88 | $60.39 | +45.73% | 5 | Feb 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $2 | $0.44 | +357.98% | 3 | Feb 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $21.04 | +42.59% | 2 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $195 → $215 | $127.54 | +68.57% | 8 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.95 | - | 2 | Aug 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $62 → $65 | $64.54 | +0.71% | 8 | Oct 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.49 | - | 2 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.61 | - | 3 | Oct 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $7.44 | - | 1 | Jan 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $6 | $516.98 | -98.84% | 1 | Apr 9, 2020 |
Abbott Laboratories
Apr 27, 2026
Reiterates: Buy
Price Target: $131
Current: $93.69
Upside: +39.82%
Edwards Lifesciences
Apr 24, 2026
Maintains: Buy
Price Target: $98 → $100
Current: $81.76
Upside: +22.31%
Boston Scientific
Apr 22, 2026
Maintains: Buy
Price Target: $90 → $80
Current: $59.00
Upside: +35.59%
Kestra Medical Technologies
Apr 7, 2026
Reiterates: Buy
Price Target: $32
Current: $22.75
Upside: +40.66%
MiniMed Group
Mar 31, 2026
Initiates: Buy
Price Target: $25
Current: $12.91
Upside: +93.72%
DexCom
Mar 9, 2026
Reiterates: Buy
Price Target: $85
Current: $60.60
Upside: +40.26%
Delcath Systems
Feb 26, 2026
Maintains: Buy
Price Target: $23 → $19
Current: $10.72
Upside: +77.24%
Insulet
Feb 18, 2026
Reiterates: Buy
Price Target: $380
Current: $186.46
Upside: +103.80%
Masimo
Feb 18, 2026
Downgrades: Neutral
Price Target: n/a
Current: $178.50
Upside: -
AtriCure
Feb 18, 2026
Reiterates: Buy
Price Target: $54
Current: $29.22
Upside: +84.80%
Feb 12, 2026
Maintains: Buy
Price Target: $17 → $15
Current: $4.35
Upside: +244.83%
Feb 6, 2026
Reiterates: Buy
Price Target: $25
Current: $9.24
Upside: +170.56%
Feb 6, 2026
Reiterates: Buy
Price Target: $88
Current: $60.39
Upside: +45.73%
Feb 5, 2026
Maintains: Buy
Price Target: $4 → $2
Current: $0.44
Upside: +357.98%
Jan 28, 2026
Reiterates: Buy
Price Target: $30
Current: $21.04
Upside: +42.59%
Oct 31, 2025
Maintains: Buy
Price Target: $195 → $215
Current: $127.54
Upside: +68.57%
Aug 20, 2025
Downgrades: Neutral
Price Target: n/a
Current: $3.95
Upside: -
Oct 14, 2024
Maintains: Buy
Price Target: $62 → $65
Current: $64.54
Upside: +0.71%
Jun 25, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.49
Upside: -
Oct 13, 2021
Downgrades: Neutral
Price Target: n/a
Current: $1.61
Upside: -
Jan 21, 2021
Downgrades: Neutral
Price Target: n/a
Current: $7.44
Upside: -
Apr 9, 2020
Maintains: Buy
Price Target: $11 → $6
Current: $516.98
Upside: -98.84%